Jagsonpal Pharmaceuticals Limited

JAGSNPHARM

INE048B01027

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 11:02:17 23/05/2024 BST			5-day change	1st Jan Change
332.2 ^INR	-3.39%		-2.02%	-14.59%

05-20	Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
03-08	Jagsonpal Pharmaceuticals Limited Launches Queezy-ER®	CI

JAGSONPAL Pharmaceuticals Ltd Announces Management Changes

April 16, 2013 at 10:02 am

JAGSONPAL Pharmaceuticals Ltd. announced that Company Secretary Mr. S. K. Mata, F.C.S. has resigned from his post and Mr. Raj Kaumar Kapoor has been appointed as Compliance officer cum Company Secretary with effect from March 20, 2013.

Latest news about Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-20	CI
Jagsonpal Pharmaceuticals Limited Launches Queezy-ER®	03-08	CI
Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes	02-02	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-02	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-03	CI
Jagsonpal Pharmaceuticals' Net Profit Soars in Fiscal Q1	03/08/23	MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	02/08/23	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23/05/23	CI
Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023	23/05/23	CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others completed the acquisition of 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar.	30/03/23	CI
Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer	13/02/23	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	08/02/23	CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes	31/12/22	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/11/22	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	09/08/22	CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes	16/07/22	CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm cancelled the acquisition of 26% stake in Jagsonpal Pharmaceuticals Limited.	19/06/22	CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/05/22	CI
Infinity Holdings to Acquire Controlling Stake in Jagsonpal Pharmaceuticals for $36 Million	22/02/22	MT
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others entered into a share purchase agreement to acquire 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar for INR 2.7 billion.	20/02/22	CI
Infinity Investment Management made an offer to acquire 26% stake in Jagsonpal Pharmaceuticals Limited for INR 1.6 billion.	20/02/22	CI
Jagsonpal Pharmaceuticals Limited Enters into an Agreement with Suvinys Developers Private Limited for Supply of Product Dydrogesterone	18/02/22	CI
Jagsonpal Pharmaceuticals Names New CFO	14/02/22	MT
Jagsonpal Pharmaceuticals Appoints New CFO	11/02/22	MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	11/02/22	CI

Chart Jagsonpal Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Companyâs therapy areas include gynecology, orthopedics, and others.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JAGSONPAL PHARMACEUTICALS LIMITED	-14.59%	109M
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+34.67%	595B
JOHNSON & JOHNSON	-2.07%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.99%	282B
ASTRAZENECA PLC	+17.04%	244B
NOVARTIS AG	+10.04%	208B
ROCHE HOLDING AG	-4.21%	205B
AMGEN INC.	+7.43%	166B